These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 28619503)

  • 1. Clinical Pharmacokinetics of Levornidazole in Elderly Subjects and Dosing Regimen Evaluation Using Pharmacokinetic/Pharmacodynamic Analysis.
    Guo B; He G; Wu X; Yu J; Cao G; Li Y; Fan Y; Chen Y; Shi Y; Zhang Y; Zhang J
    Clin Ther; 2017 Jul; 39(7):1336-1346. PubMed ID: 28619503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and Pharmacodynamics of Levornidazole in Patients With Intra-abdominal AnaerobicInfection.
    Wu H; Xie S; Yu J; Chen Y; Wu J; Guo B; Zhu Z; Zhou Y; Wang Z; Zhang J
    Clin Ther; 2018 Sep; 40(9):1548-1555. PubMed ID: 30146271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of levornidazole in healthy subjects and patients, and sequential dosing regimen proposal using pharmacokinetic/pharmacodynamic analysis.
    Cao Y; Li Y; Guo B; Zhang J; Wu X; Yu J; Cao G; Fan Y; Wu H
    Int J Antimicrob Agents; 2023 Apr; 61(4):106754. PubMed ID: 36773938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Vitro Anaerobic Pharmacokinetic/Pharmacodynamic Model to Simulate the Bactericidal Activity of Levornidazole Against Bacteroides fragilis.
    Hu J; Zhang J; Chen Y; Liang W; Wu S
    Clin Ther; 2017 Apr; 39(4):828-836. PubMed ID: 28363695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of Levornidazole Tablet in Healthy Chinese Subjects and Proposed Dosing Regimen Based on Pharmacokinetic/Pharmacodynamic Analysis.
    Wu H; Wang Z; Wang Y; Yu J; Fan Y; Li Y; Wang J; Cao G; Guo B; Chen Y; Liu X; Bian X; Wu J; Li H; Wu X; Zhang J
    Infect Dis Ther; 2021 Jun; 10(2):911-923. PubMed ID: 33826105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the in vitro activity of levornidazole, its metabolites and comparators against clinical anaerobic bacteria.
    Hu J; Zhang J; Wu S; Zhu D; Huang H; Chen Y; Yang Y; Zhang Y
    Int J Antimicrob Agents; 2014 Dec; 44(6):514-9. PubMed ID: 25301712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and safety of injected ornidazole compared to its enantiomer levornidazole in healthy Chinese subjects.
    Liu Y; Zhang Y; Xue W; Wang J; Bai W; Wang T; Liu Y; Tang K; Qin J; Li K; Wang X
    Int J Clin Pharmacol Ther; 2023 Dec; 61(12):543-550. PubMed ID: 37840522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved pharmacokinetic profile of levornidazole following intravenous infusion of 750mg every 24h compared with 500mg every 12h in healthy Chinese volunteers.
    Cao Y; Wu X; Chen Y; Guo B; Yu J; Cao G; Zhang J; Shi Y; Zhang Y
    Int J Antimicrob Agents; 2016 Mar; 47(3):224-8. PubMed ID: 26920104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerability and Pharmacokinetics of Contezolid at Therapeutic and Supratherapeutic Doses in Healthy Chinese Subjects, and Assessment of Contezolid Dosing Regimens Based on Pharmacokinetic/Pharmacodynamic Analysis.
    Wu J; Wu H; Wang Y; Chen Y; Guo B; Cao G; Wu X; Yu J; Wu J; Zhu D; Guo Y; Yuan H; Hu F; Zhang J
    Clin Ther; 2019 Jun; 41(6):1164-1174.e4. PubMed ID: 31126694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantification of levornidazole and its metabolites in human plasma and urine by ultra-performance liquid chromatography-mass spectrometry.
    Cao Y; Zhao M; Wu X; Guo B; Chen Y; Yu J; Cao G; Zhang J; Shi Y; Zhang Y
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jul; 963():119-27. PubMed ID: 24953495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of the sulfate and glucuronide conjugates of levornidazole in human plasma and urine, and levornidazole and its five metabolites in human feces by high performance liquid chromatography-tandem mass spectrometry.
    He G; Guo B; Zhang J; Li Y; Wu X; Fan Y; Chen Y; Cao G; Yu J
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Apr; 1081-1082():87-100. PubMed ID: 29518721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole.
    Sprandel KA; Drusano GL; Hecht DW; Rotschafer JC; Danziger LH; Rodvold KA
    Diagn Microbiol Infect Dis; 2006 Aug; 55(4):303-9. PubMed ID: 16887471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetics Study of Contezolid (MRX-I), a Novel Oxazolidinone Antibacterial Agent, in Chinese Patients.
    Li L; Wu H; Chen Y; Yuan H; Wu J; Wu X; Zhang Y; Cao G; Guo B; Wu J; Zhao M; Zhang J
    Clin Ther; 2020 May; 42(5):818-829. PubMed ID: 32389326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating biapenem dosage regimens in intensive care unit patients with Pseudomonas aeruginosa infections: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
    Hang Y; Chen Y; Xue L; Sun S; Liu L; Gao J; Xie C; Zhang X; Zhu J; Jin J; Miao L
    Int J Antimicrob Agents; 2018 Mar; 51(3):484-487. PubMed ID: 28709989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic/pharmacodynamic research on three different infusion time regimens of linezolid in healthy Chinese volunteers.
    Cai Y; Bai N; Liu X; Liang B; Wang J; Wang R
    Int J Clin Pharmacol Ther; 2015 Sep; 53(9):765-71. PubMed ID: 26227096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determining optimal dosing regimen of oral administration of dicloxacillin using Monte Carlo simulation.
    Yu W; Ji J; Xiao T; Ying C; Fang J; Shen P; Xiao Y
    Drug Des Devel Ther; 2017; 11():1951-1956. PubMed ID: 28721014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using Monte Carlo simulation to determine optimal dosing regimen for cefetamet sodium for injection.
    Li C; Sun J; Miao J; Qin Y; Wang Y; Yu R; Xiao Y
    J Chemother; 2016 Jun; 28(3):172-9. PubMed ID: 25252727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics of pulse dosing versus standard dosing: in vitro metronidazole activity against Bacteroides fragilis and Bacteroides thetaiotaomicron.
    Ibrahim KH; Gunderson BW; Hermsen ED; Hovde LB; Rotschafer JC
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4195-9. PubMed ID: 15504841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of YK-1169 in healthy subjects and pharmacokinetic/pharmacodynamic analysis by Monte Carlo simulation.
    Li Y; Yan B; Guo S; Tian M; Li Y; Tong H; Yu Y; Shao J; Xin Y; Chen H; Xu B; Li X
    Br J Clin Pharmacol; 2023 Oct; 89(10):3067-3078. PubMed ID: 37255194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae.
    Noreddin AM; Hoban DJ; Zhanel GG
    Int J Antimicrob Agents; 2005 Aug; 26(2):120-5. PubMed ID: 16046101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.